Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.

Nonalcoholic fatty liver disease ups risk of death

13 Aug 2019

Nonalcoholic fatty liver disease (NAFLD) heightens the risk of all-cause death but not from cardiovascular diseases (CVD) or cancer, reports a recent meta-analysis.

Accessing the databases of PubMed and Embase, researchers retrieved 14 studies that investigated the effect of NAFLD on mortality risk. Reports that used NAFLD patients as the reference group or assessed mortality in patients undergoing bariatric surgery or liver transplantation were ineligible. The Newcastle-Ottawa scale was used to evaluate methodological quality.

A total of 24,188 deaths were reported in the cumulative sample of 498,259 participants. Pooled analysis revealed a significantly higher death risk in NAFLD patients (hazard ratio [HR], 1.34, 95 percent CI 1.17–1.54), though the evidence had substantial heterogeneity (p<0.01).

Subsequent subgroup analyses found that NAFLD was a significant mortality hazard in women (four studies; HR, 1.49, 1.15–1.93) but not in men (four studies, HR, 1.08, 0.83–1.41). In contrast, there were no meaningful effect modifications according to age, sex, NAFLD severity, the presence of fibrosis or cirrhosis, follow-up duration, comorbidities, and the method used to diagnose NAFLD.

The effect of NAFLD on death risk appeared to be robust, as excluding four studies with large sample sizes did not change the principal findings. NAFLD also exerted a similar effect on the likelihood of death from liver disease (HR, 2.53, 1.23–5.18).

On the other hand, NAFLD had no apparent effect on the risk of death from CVDs (HR, 1.13, 0.92–1.38) and cancer (HR, 1.05, 0.89–1.25).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
4 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 5 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, 2 days ago
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.